Pros | - | |||
Cons | - |
INDMoney rank | - | |||
Category,Subcateogry | Equity,Sector - Healthcare | |||
Fund Age | 3 Years | |||
Fund Size | 214 Cr | |||
Min Investment | SIP ₹500 Lumpsum ₹5000 | |||
Expense Ratio | 0.47% | |||
Exit Load | 1% | |||
Benchmark Index | Nifty Healthcare TR INR |
No of Holdings | 40 | |||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (16.22%) Divi's Laboratories Ltd (5.96%) Lupin Ltd (5.78%) Suven Pharmaceuticals Ltd (5.39%) Apollo Hospitals Enterprise Ltd (5.16%) | |||
No of Sectors | 3 | |||
Top 3 Sectors | Health (95.43%) Basic Materials (3.54%) Industrial (1.03%) | |||
Equity % | 97.95% | |||
Debt % | - | |||
P/E | 37.64 | |||
P/B | 5.87 | |||
Credit Quality | - | |||
Modified Duration | - | |||
YTM | - |
1-Month Return | 5.25% | |||
3-Month Return | -3.57% | |||
6-Month Return | -8.32% | |||
1-Year Return | 17.5% | |||
3-Year Return | 19.58% | |||
5-Year Return | - |
Sharpe | 0.84 | |||
Alpha | 2.89 | |||
Beta | 0.91 | |||
Standard Deviation | 16.41 | |||
Information Ratio | 0.51 |
Description | ITI Pharma and Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | |||
Managers | - |